|
|
|
|
|
July 30-31, 2021 • Hilton Anatole, Dallas, TX |
|
OncLive® is eager to attend the 20th Annual International Congress on the Future of Breast Cancer® West in Dallas, TX with our partners at PER®. The two-day event offers expert-led lectures, case discussions, and interactive Q&A sessions on the latest data in breast cancer. Attendees will leave with information to help care for their breast cancer patients. |
|
We encourage you to register and join us in-person at the OncLive® Events non-CME Product Theaters. There you will have the opportunity to network and enjoy a meal with breast cancer experts. |
|
|
|
|
|
|
Sara Hurvitz, MD
Director
Breast Cancer Clinical Research Program
Co-Director
Santa Monica – UCLA Outpatient Hematology/Oncology Practice
Associate Professor of Medicine
Division of Hematology/Oncology
David Geffen School of Medicine
UCLA
Santa Monica, CA
|
|
|
|
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer
Research
Baylor University Medical Center
Director
Breast Cancer Research Program
Texas Oncology
The US Oncology Network
Dallas, TX
|
|
|
|
|
We know the last year-plus has been difficult being apart and we are excited to see you again. Your health and safety is of utmost importance to us. Please review our MJH Safe Commitment at the bottom of this email to better understand the safety precautions that will be in-place at this and all future in-person events. |
|
|
We look forward to being Your Link to Everything Oncology. |
|
|
|
|
SAFETY PRECAUTIONS/PERSONAL ACCOUNTABILITY COMMITMENT
|
|
By attending this program, you agree to abide by and engage in certain health- and safety beneficial conduct while attending the event, including providing proof at check-in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days before the program. For information on the specific safety precautions that will be in place, please visit www.mjhlifesciences.com/mjhsafe and click on Health & Safety Precautions. |
|
|
|
|
|
|
|
